Imprimis Pharmaceuticals Announces 2015 Annual Meeting Of Stockholders

SAN DIEGO, April 2, 2015 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced that its annual meeting of stockholders will be held on May 12, 2015 at 9:00 a.m. Pacific time at the offices of Morrison & Foerster, LLP, 12531 High Bluff Drive, Suite 100, San Diego, CA 92130. Stockholders of Imprimis Pharmaceuticals who hold shares as of the close of business on the record date, April 9, 2015, will be entitled to receive notice of and vote at the annual meeting.

Imprimis Pharmaceuticals Logo

ABOUT IMPRIMIS PHARMACEUTICALS

San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at accessible prices. Imprimis’ business is focused on its proprietary ophthalmology and urology drug formulations. The company’s pioneering ophthalmology formulation portfolio is disrupting the multi-billion dollar eye drop market, addressing patient compliance issues and providing other medical and economic benefits to patients. Imprimis recently launched its urology business, which includes a patented formulation to address patients suffering from interstitial cystitis. For more information about Imprimis, please visit the company’s corporate website at www.ImprimisPharma.com; ophthalmology business websites at www.GoDropless.com and www.LessDrops.com; and urology business website at www.DefeatIC.com.

Investor Contact
Bonnie Ortega
bortega@imprimispharma.com
858.704.4587

Logo - http://photos.prnewswire.com/prnh/20150108/167712LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/imprimis-pharmaceuticals-announces-2015-annual-meeting-of-stockholders-300059799.html

SOURCE Imprimis Pharmaceuticals, Inc.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC